This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Treatment Adherence  • Cardiovascular System  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Thomas C. Bailey, MD; Laura A. Noirot, BS; Amy Blickensderfer, PharmD; Erin Rachmiel, PharmD; Robyn Schaiff, PharmD; Anthony Kessels, PharmD; Alan Braverman, MD; Anne Goldberg, MD; Brian Waterman, MPH; W. Claiborne Dunagan, MD

Arch Intern Med. 2007;167(6):586-590.

Background  Translating guidelines into clinical practice has proved to be quite difficult, even when the guidelines are well accepted and noncontroversial. Both computerized reminders and academic detailing have been effective in changing physician prescribing behavior. In this study, we sought to use these methods, mediated by clinical pharmacists, to improve adherence to the secondary prevention guidelines in hospitalized patients with myocardial infarction.

Methods  A randomized, prospective study was performed in which computerized alerts identifying hospitalized patients with elevated troponin I levels were routed to clinical pharmacists. The pharmacists then conducted academic detailing for physicians caring for patients with acute myocardial infarction who were randomized to the intervention group. Patients in the control group received standard care. The main outcome measure was the proportion of patients discharged on a regimen of aspirin, β-blockers, angiotensin-converting enzyme inhibitors, and statins.

Results  The intervention had a significant impact on the proportion of patients discharged on a regimen of angiotensin-converting enzyme inhibitors (328/365 [89.9%] vs 409/488 [83.8%], intervention vs control, respectively, P = .02), and statins (344/365 [94.2%] vs 436/488 [89.3%], P = .02). There was no statistical impact on β-blocker (350/365 [95.9%] vs 448/488 [91.8%], P = .10) or aspirin use (352/365 [96.4%] vs 471/488 [96.5%], P = .87). When all 4 classes were considered together, 305 (83.6%) of 365 patients vs 343 (70.3%) of 488 patients were discharged on a regimen of all secondary prevention medications to which they did not have a contraindication (P<.001).

Conclusion  A computerized alert with pharmacist-mediated academic detailing is an effective means to increase adherence to secondary prevention guidelines for coronary heart disease.

Author Affiliations: Department of Medicine, Washington University School of Medicine, (Drs Bailey, Braverman, Goldberg, and Dunagan and Ms Noirot), Department of Pharmacy, Barnes-Jewish Hospital (Drs Blickensderfer, Rachmiel, Schaiff, and Kessels), and BJC Healthcare (Drs Bailey and Dunagan and Mr Waterman) St Louis, Mo. Dr Blickensderfer is now with Amylin Pharmaceuticals, San Diego, Calif; Dr Rachmiel is now with Berkshire Medical Center, Pittsfield, Mass; and Dr Schaiff is now with Pfizer Inc, New York, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Implementation and evaluation of electronic clinical decision support for compliance with pneumonia and heart failure quality indicators
Niemi et al.
Am J Health Syst Pharm 2009;66:389-397.
ABSTRACT | FULL TEXT